Table 2.
Results of Cox proportional hazard regression analysis of the risk of all-cause mortality among patients with cervical adenocarcinoma or squamous cell carcinoma who received curative surgery
| Crude HR (95% CI) | Adjusted HR* (95% CI) | P-value | ||
|---|---|---|---|---|
| Pathologic type | SCC | 1 | 1 | <.0001 |
| Adenocarcinoma | 1.88 (1.60, 2.21) | 2.34 (1.96, 2.79) | ||
| Age | 0-39 | 1 | 1 | <.0001 |
| 40-49 | 1.17 (0.87, 1.57) | 1.01 (0.75, 1.36) | ||
| 50-59 | 1.57 (1.19, 2.07) | 1.07 (0.81, 1.43) | ||
| 60-69 | 2.04 (1.52, 2.74) | 1.25 (0.91, 1.70) | ||
| 70+ | 4.71 (3.50, 6.33) | 2.89 (2.10, 3.99) | ||
| AJCC pathologic stage | I | 1 | 1 | <.0001 |
| IIA | 2.75 (2.00, 3.80) | 2.05 (1.46, 2.87) | ||
| IIB | 3.49 (2.58, 4.73) | 2.31 (1.66, 3.22) | ||
| III | 6.18 (5.17, 7.38) | 4.76 (3.79, 5.98) | ||
| IVA | 16.95 (13.31, 21.59) | 10.07 (7.54, 13.46) | ||
| Surgical margin | No residual | 1 | 1 | <.0001 |
| Residual | 3.33 (2.74, 4.06) | 1.80 (1.45, 2.24) | ||
| Unknown | 1.89 (1.45, 2.48) | 1.38 (1.04, 1.83) | ||
| Grade | I (well differentiated) | 1 | 1 | .0017 |
| II (moderately differentiated) | 1.30 (0.98, 1.72) | 1.19 (0.88, 1.61) | ||
| III (poorly differentiated) | 1.63 (1.20, 2.22) | 1.41 (1.01, 1.95) | ||
| IV (undifferentiated) | 4.69 (2.32, 9.50) | 3.21 (1.56, 6.60) | ||
| Missing | 0.62 (0.45, 0.87) | 0.96 (0.68, 1.37) | ||
| Adjuvant treatment | No adjuvant | 1 | 1 | .0381 |
| Adjuvant CCRT | 3.41 (2.84, 4.09) | 0.96 (0.76, 1.22) | ||
| Adjuvant sequential CT and RT | 5.66 (4.17, 7.70) | 1.52 (1.08, 2.15) | ||
| Adjuvant RT | 2.92 (2.40, 3.56) | 1.11 (0.88, 1.41) | ||
| IC brachytherapy | 2.81 (2.41, 3.27) | 1.14 (0.92, 1.50) | .1307 | |
| Year of diagnosis | 2007-2009 | 1 | 1 | .0553 |
| 2010-2012 | 1.05 (0.88, 1.25) | 0.86 (0.72, 1.02) | ||
| 2013-2015 | 0.96 (0.77, 1.21) | 0.77 (0.61, 0.97) | ||
| CCI score | 0 | 1.00 | 1 | <.0001 |
| 1 | 1.52 (1.24, 1.85) | 1.24 (1.00, 1.53) | ||
| 2+ | 2.27 (1.79, 2.88) | 1.76 (1.37, 2.28) | ||
| Income | <NTD 18,000 | 1 | 1 | .0051 |
| NTD 18,000-22,500 | 0.78 (0.65, 0.94) | 0.74 (0.61, 0.89) | ||
| NTD 22,500-30,000 | 0.73 (0.57, 0.95) | 0.73 (0.62, 0.85) | ||
| NTD 30,000+ | 0.72 (0.58, 0.88) | 0.72 (0.58, 0.89) | ||
| Hospital level | Medical center | 1 | 1 | .0422 |
| Nonmedical center | 1.36 (1.16, 1.59) | 1.19 (1.01, 1.41) | ||
| Region | North | 1 | 1 | .2881 |
| Central | 1.06 (0.86, 1.30) | 1.05 (0.85, 1.30) | ||
| South/East | 1.31 (1.10, 1.55) | 1.16 (0.96, 1.39) |
*
All the variables included in Table 2 were used in the multivariate analysis.
CCRT, concurrent chemoradiotherapy; Gy, gray; SCC, squamous cell carcinoma; FIGO, International Federation of Gynecology and Obstetrics; EBRT, external beam radiotherapy; CCI, Charlson comorbidity index; MG, milligrams; HR, hazard ratio; CI, confidence intervals; NTD, New Taiwan dollar; IC, intracavitary; AJCC, American Joint Committee on Cancer; CT, chemotherapy; RT, radiotherapy.